The metacognitions about symptoms control scale: development and concurrent validity by Fernie, B.A. et al.
The Metacognitions about Symptoms Control Scale                                                                                                                                            April 2014 
 
 1 
The Metacognitions about Symptoms Control Scale:  
Development and concurrent validity 
 
 
 
Word count: 4,830 (all sections included) 
Full Length Paper 
 
Bruce A. Fernie 
King’s College London, Institute of Psychiatry, Department of Psychology,  
London, UK 
CASCAID, South London & Maudsley NHS Foundation Trust, London, UK 
 
Lorraine Maher-Edwards 
Chelsea and Westminster NHS Foundation Trust, London, UK 
 
Gabrielle Murphy 
Fatigue Service, Royal Free London NHS Foundation Trust, UK 
 
Ana V. Nikčević 
Faculty of Arts and Social Sciences, Kingston University,  
Kingston upon Thames, UK 
 
Marcantonio M. Spada 
London South Bank University, London, UK 
 
 
Revision 2 
 
 
April 2014 
 
This is the peer reviewed version of the following article: Fernie, B. A., Maher-Edwards, L., 
Murphy, G., Nikčević, A. V., and Spada, M. M. (2015), The Metacognitions about Symptoms 
Control Scale: Development and Concurrent Validity. Clin. Psychol. Psychother., 22, 443–
449., which has been published in final form at http://dx.doi.org/10.1002/cpp.1906 . This 
article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Self-Archiving." 
 
 
 
Acknowledgements 
 
Author Bruce A. Fernie receives salary support from the National Institute for Health Research 
(NIHR) Mental Health Biomedical Research Centre and Dementia Research Unit at South London 
and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those 
of the author and not necessarily those of the NHS, the NIHR or the Department of Health. 
The Metacognitions about Symptoms Control Scale                                                                                                                                            April 2014 
 
 2 
 
 
Author Notes 
 
Correspondence should be addressed to: Marcantonio M. Spada, Department of Psychology, 
Faculty of Arts and Human Sciences, London South Bank University, United Kingdom. Tel. +44 
(0)20 7815 5760, e-mail spadam@lsbu.ac.uk.  
 
Abstract 
Objective: This paper presents the development and preliminary validation of a self-report 
instrument designed to measure metacognitions pertaining to symptoms control in the form of: (1) 
symptoms focusing; and (2) symptoms conceptual thinking. Methods: 124 patients (95 female and 
29 male) presenting with Chronic Fatigue Syndrome (CFS) contributed data to the study to test the 
structure and psychometric properties of the Metacognitions about Symptoms Control Scale 
(MaSCS). Results: A principal components factor analysis indicated that a two-factor solution best 
fitted the data. The factors were labelled positive and negative metacognitions about symptoms 
control. Further analyses revealed that both factors had good internal consistency. Correlation 
analyses established preliminary concurrent validity, indicating that both positive and negative 
metacognitions about symptoms control were significantly associated with levels of fatigue in CFS. 
Regression analysis revealed that positive and negative metacognitions about symptoms control 
significantly predicted fatigue severity when controlling for anxiety and depression. Conclusions: 
The newly developed instrument may help future research that examines the role of metacognitions 
in CFS, as well as aiding clinical assessment and case formulation. 
 
Key Practitioner Message 
The MaSCS is a useful first instrument to assess metacognitions in CFS. 
The MaSCS may help to deepen our understanding of symptoms control (symptoms focusing and 
conceptual thinking about symptoms) in the experience of CFS symptoms. 
Assessing and conceptualising symptoms control through the MaSCS may aid treatment of CFS.  
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1. Introduction 
Individuals with Chronic Fatigue Syndrome (CFS) often present with a myriad of symptoms 
(Nisenbaum, Reyes, Unger, & Reeves, 2004), chiefly characterised by fatigue (Sharpe et al., 1991). 
Flu-like symptoms without the presence of fever are often reported (Komaroff et al., 1996), 
alongside cognitive deficits and neurological symptoms (Friedberg, Dechene, McKenzie Ii, & 
Fontanetta, 2000). 
A series of systematic reviews have suggested that Cognitive Behaviour Therapy (CBT; 
Price, Mitchell, Tidy, & Hunot, 2008) and Graded Exercise Therapy (GET; Edmonds, McGuire, & 
Price, 2004) are at least moderately effective treatments for CFS. More recently, these reviews have 
been supported by the publication of the PACE trial, a large multi-centred randomised trial that 
compared the effectiveness of adding adaptive pacing therapy (APT), GET, or CBT to standardised 
medical care (SMC; White et al., 2011). This study found that CBT and GET were moderately 
effective treatments for CFS, and that there was no difference between APT and SMC, and SMC 
alone. CBT and GET remain the two treatments recommended by the National Institute of Clinical 
Excellence guidelines (2007) for mild and moderate categories of CFS; however, recovery rates in 
CFS occupy a broad range, depending on the definition of recovery used. Knoop, Bleijenberg, 
Gielissen, van der Meer, and White (2007) suggest that between 23% and 69% of CFS patients 
make a full recovery following a course of CBT. Whilst this finding is encouraging, it suggests that 
it may be beneficial to examine refining CBT protocols to enhance treatment outcomes. 
Traditional CBT protocols for CFS attempt to address factors involved in the maintenance 
of the condition such as all-or-nothing patterns of behaviour, maladaptive coping strategies, and 
unhelpful beliefs about symptoms and activity (White, Sharpe, Chalder, DeCesare, & Walwyn, 
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2007). However, recent research has implicated cognitive processes in CFS that offer themselves as 
potential new targets for intervention. For example conceptual thinking, such as self-reported 
health-related worry and preoccupation with health threats (Aggarwal, McBeth, Zakrzewska, Lunt, 
& Macfarlane, 2006), has been found in CFS, as well as attentional biases for processing health-
threat information (Hou, Moss-Morris, Bradley, Peveler, & Mogg, 2008).  
Metacognitions can be defined as “stable knowledge or beliefs about one’s own cognitive 
system, and knowledge about factors that affect the functioning of the system; the regulation and 
awareness of the current state of cognition, and appraisal of the significance of thought and 
memories” (p. 302; Wells, 1995). Metacognitions are divided into two broad sets (Wells & 
Matthews, 1994; Wells, 2000): (1) positive metacognitions about control strategies that impact on 
inner events such as “Worry will help me get things sorted out in my mind” or “If I ruminate I will 
find a solution”; and (2) negative metacognitions concerning the significance, controllability and 
danger of inner events, such as “It is bad to have sensation X” or “My worry is out of control”. 
Metacognitions are believed to play a fundamental role in activating control strategies (such as 
attention to threat, conceptual thinking and thought suppression) in response to inner events (such 
as thoughts, emotional states or physical symptoms) that result in the exacerbation and maintenance 
of psychological distress. In support of this view, metacognitions have been found to be associated 
with a wide array of psychological and behavioural problems (for a full review, see Wells, 2008; 
Wells, 2013). Related research by Dimaggio and colleagues (2007) and Lysaker and colleagues 
(2014) has also highlighted the importance of an awareness of one’s own mental state and the 
ability to recognize the mental states of others in personality disorder. This is of particular relevance 
in studying metacognition in CFS because of the high prevalence of personality disorders found in 
CFS (e.g. Henderson & Tannock, 2004).  
Recent research on CFS has suggested that metacognitions about the need to control 
thoughts and cognitive confidence predict symptom severity in CFS when controlling for negative 
emotion (Lorraine Maher-Edwards, Fernie, Murphy, Wells, & Spada, 2011). A later study on CFS 
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patients, by Maher-Edwards and colleagues (Maher-Edwards, Fernie, Murphy, Nikčević, & Spada, 
2012), identified positive metacognitions about symptoms focusing and conceptual thinking about 
symptoms. The authors argued that such beliefs may activate these conceptual processes in response 
to CFS symptoms. Negative metacognitions about the drawbacks (worsening of negative affect) and 
uncontrollability of symptoms focusing and conceptual thinking about symptoms were also 
identified. The authors argued that these beliefs could play a role both in worsening the experience 
of fatigue because of worsening negative affect (Sohl & Friedberg, 2008) as well as result in the 
perseveration of fatigue because attempts at terminating conceptual processing would become less 
likely.   
The current study builds on these findings by presenting the development and preliminary 
validation of an instrument designed to assess CFS-specific metacognitions about symptoms control 
in the form of symptoms focusing and conceptual thinking about symptoms. The instrument was 
built from items derived from the aforementioned studies, clinical experience, and theory. We 
hypothesized that this newly developed instrument would have a significant association with the 
severity of CFS symptoms and that this relationship would be maintained when controlling for 
anxiety and depression. 
2. Methods 
2.1. Participants 
One hundred and twenty four patients (95 female and 29 male) referred to the Fatigue 
Service at the Royal Free London NHS Foundation Trust, UK, were recruited for the purposes of 
this study. All patients were given a formal diagnosis of CFS according to the Oxford Criteria 
(Sharpe et al., 1991). The self-reported mean time since the onset of symptoms was 9.1 years (range 
1-45). Prior to diagnosis, all other known causes for fatigue were excluded on history, examination 
and by investigation. The latter included blood and urine testing for most of the common, and some 
of the less common, causes of fatigue such as anaemia, diabetes, autoimmune conditions such as 
coeliac disease, common variable immunodeficiency, and thyroid dysfunction as well as screen for 
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infection and inflammation. A full physical examination was also conducted, including standing and 
lying blood pressure measurements, specifically to exclude markers of quiescent conditions that 
may not show on blood tests and orthostatic hypotension and postural orthostatic tachycardia 
syndrome.  
Additional inclusion criteria were: (1) 18 years of age or above; (2) consenting to the study; 
(3) understanding spoken and written English; (4) the absence of a diagnosis of major depressive 
disorder or psychosis. The mean age of the sample was 41.7 years (range 18-70). Forty three 
patients had previously undertaken a course of CBT, four patients had undertaken a course of GET, 
24 patients had undertaken an alternative therapy (defined as a therapy not recommended in the 
NICE guidelines for CFS), and 11 patients had undertaken both an alternative therapy together with 
either or both CBT and GET. 
2.2. Self-Report Instruments 
2.2.1.Chalder Fatigue Questionnaire (CFQ; Chalder et al., 1993) 
The CFQ consists of 14 items assessing levels of mental (8 items; e.g. “Do you need to rest 
more?”) and physical (6 items; e.g. Do you have problems with tiredness?”) fatigue over the 
previous month. Higher scores indicate higher levels of mental and physical fatigue. The CFQ 
possesses good psychometric properties (Chalder et al., 1993)and is recommended for use in the 
Adult Minimum Dataset for assessing severity of CFS (NICE, 2007). The instrument utilizes a four-
point Likert-type response form. Items responded to as ‘better than usual’ and ‘no worse than usual’ 
are sometimes scored as 0, and items responded to as ‘worse than usual’ and ‘much worse than 
usual’ are scored as 1. The present study scored responses as 1, 2, 3, or 4 respectively, with higher 
scores representing more fatigue. This scoring approach was taken to heighten the sensitivity of the 
instrument, retaining its original psychometric properties, for the purpose of elucidating the 
relationship between CFS symptoms and the newly developed instrument. 
2.2.2.RAND Short Form 36 Physical Functioning (SF-36 PF; Ware & Sherbourne, 1992) 
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The RAND SF-36 PF consist of 10 items assessing daily activities such as climbing stairs, 
lifting or carrying groceries, walking, and bathing. It is the Physical Functioning factor of the 
RAND Short Form 36 Health Questionnaire that assesses function in different areas such as general 
health, social functioning, mental health and limitations in role activities because of physical or 
emotional problems (Ware & Sherbourne, 1992). Participants indicate how much their health limits 
them in these activities, responding to individual items by choosing between “A lot”, “A little” or 
“Not at all”. Higher scores indicate higher levels of physical functioning. The RAND SF-36 PF is a 
widely used, reliable and valid instrument with population norms and normative data for a variety 
of medical conditions (Ware & Kosinski, 2001). 
2.2.3. Depression Anxiety Stress Scale 21 (DASS-21;  Lovibond & Lovibond, 1995) 
The DASS-21 consists of 21 items assessing levels of depression (e.g. “I felt that I had 
nothing to look forward to”), anxiety (e.g. “I felt scared without any good reason”) and stress (e.g. 
“I was intolerant of anything that kept me from getting on with what I was doing”). Higher scores 
indicate higher levels of anxiety, depression and stress. The DASS-21 has been reported to have 
adequate psychometric properties(Henry & Crawford, 2005), with the factors of the full version 
having been shown to correlate with validated measures of anxiety and depression (Crawford & 
Henry, 2003). This study utilized the anxiety and depression factors. 
2.2.4. Metacognitions about Symptoms Control Scale (MaSCS) 
The MaSCS items were derived from responses to an earlier metacognitive profiling study 
in CFS (Maher-Edwards et al., 2012), from the authors’ clinical experience, and from deductions 
based on theory. The raw MaSCS consisted of 19 items and utilised a four-point Likert-type 
response format, with the options “Do not agree”, “Agree Slightly”, “Agree moderately”, and 
“Agree strongly”.  The items were presented with the following preamble: 
This scale is concerned with how people with CFS/ME experience and cope with their 
symptoms. Listed below are a number of beliefs that people have expressed. Please read each item 
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and say how much you generally agree with it by circling the one appropriate number. There are 
no right or wrong answers. 
 
 
2.3. Procedure 
Ethics approval was obtained from the local research ethics committee. Patients received the 
study pack through the post. They were informed that the study aimed to investigate how people 
with CFS think about and experience symptoms. Patients were informed that participation was 
voluntary, that confidentiality would be protected, and gave informed consent to participate in the 
study. 
2.4. Data Analysis 
 A principal components analysis was conducted on the data. Internal consistency was 
assessed by calculating Cronbach’s Alphas for all factors and by calculating alphas-if-item-deleted. 
The data from was also assessed for normality with Kolmogorov-Smirnov tests. Concurrent validity 
was assessed by computing correlations between the factors of the MaSCS and factors of the CFQ 
and SF-36 PF. A regression analysis was conducted to assess the relationship between the MaSCS 
and CFQ when controlling for anxiety and depression. 
3. Results 
3.1. Principal Components Analysis of the MaSCS 
 A principal components analysis was conducted on the original items of the MaSCS (19 
items). Scree tests for the raw instrument suggested a two-factor solution with Eigen values of 6.0 
and 3.9. Indicators of the latent variables were assessed using a Promax rotation with a Kappa of 
four. This oblique rotation enabled us to assess the correlation between factors (r=.20). The two 
factors combined accounted for 51.9% of the variance. 
 Item selection was based on the following criteria: (1) if an item loaded less than .4 on a 
factor it was discarded; (2) if an item loaded more than .4 on both factors it was discarded; and (3) 
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if an item loaded 0.4 or greater on a factors but it’s loading on the other factor was within .2, it was 
discarded. 
The revised instrument retained 17 items, with the distribution of nine items on one factor 
and eight on the other. For the revised instrument, the two-factor solution accounted for 55.3% of 
the variance (with Eigen values of 5.6 and 3.9) and the estimated correlation between the factors 
was .17. Table 1 shows the factor loadings for the revised instrument. The first factor of the 
instrument was named positive metacognitions about symptoms control and the second factor 
negative metacognitions about symptoms control as these appeared to reflect their content. 
3.2. Internal Consistency of the MaSCS 
 Calculations of the internal consistency of the two factors of the MaSCS revealed 
Cronbach’s Alphas of α=.89 for positive metacognitions about symptoms control and α=.88 for 
negative metacognitions about symptoms control indicating good reliability. Table 2 shows 
Cronbach’s Alphas if items were deleted and reveal that the internal consistency of both factors of 
the MaSCS would not be improved by removing any of the items. 
3.3. Correlation Analysis between the MaSCS, CFQ and SF-36 PF 
 A series of Kolmogorov-Smirnov tests were conducted, suggesting that the distributions of 
all variables differed significantly from normality. As a result, a Spearman’s Rho correlation matrix 
was generated (Table 3) showing that there were positive and significant relationships between both 
factors of the MaSCS and the CFQ. In addition, the matrix revealed that there was a significant and 
negative relationship between negative metacognitions about symptoms control and the SF-36 PF. 
3.4. Regression Analysis to Indentify Predictors of CFQ 
 Several steps were taken to assess whether multicollinearity was present in the data. Firstly, 
the correlation matrix revealed no substantial correlations (r>.9) between the predictor variables. 
Secondly, an inspection of the ranges of the Tolerance Index (TI; 0.41-0.95) and the Variance 
Inflation Factor (VIF; 1.052-2.439) for all predictor variables supported the absence of 
multicollinearity. Histograms and normality plots suggested that the residuals were normally 
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distributed. Plots of the regression standardized residuals against the regression standardized 
predicted values suggested that the assumptions of linearity and homoscedascity were met. 
Additionally, the Durbin-Watson test suggested that the assumption of independent errors is 
tenable.  
 Table 4 presents a two-step hierarchical regression analysis with CFQ as the outcome 
variable. The predictor variables consisted of  anxiety and depression on step 1 and both factors of 
the MaSCS on step 2. Results from this analysis indicated that both factors of the MaSCS 
contributed variance over and above anxiety and depression to CFQ scores. In the final step of the 
regression model both MaSCS factors and depression remained the only significant predictors of 
CFQ scores.  
4. Discussion 
In this study, we have presented the development and preliminary validation of an 
instrument aimed at assessing, in CFS patients, metacognitions about symptoms control in the form 
of symptom focusing and conceptual thinking about symptoms. This follows directly from earlier 
research that implicated metacognitions in CFS symptom severity (Lorraine Maher-Edwards et al., 
2011) and research that has identified CFS-specific metacognitions (Maher-Edwards et al., 2012). 
The principal components analysis revealed that the MaSCS has two factors: positive and negative 
metacognitions about symptoms control. Correlation analyses also revealed significant and positive 
relationships between both of these factors and symptom severity, and a significant and negative 
relationship between negative metacognitions about symptoms control and physical functioning. 
Furthermore, the two factors of the MaSCS significantly predicted fatigue when controlling for both 
anxiety and depression. These findings are consistent with earlier studies implicating 
metacognitions in CFS (Maher-Edwards et al., 2012; Lorraine Maher-Edwards et al., 2011). 
This study found that only negative metacognitions about symptoms control was 
significantly associated with physical functioning. Perhaps this is because physical functioning is 
secondary to the experience of fatigue symptoms in CFS: i.e. fatigue leads to avoidance, resulting in 
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deconditioning and a reduction in physical functioning. If this mechanism is correct, it might 
explain why positive metacognitions about symptoms control were significantly associated with 
fatigue but not physical functioning. 
Future studies might explore whether the MaSCS predicts, when controlling for negative 
emotion, levels of symptoms focus and conceptual thinking about symptoms. Further studies could 
also examine whether interventions designed to modify metacognitions can help to reduce levels of 
symptom severity by reducing the conceptual processing of symptoms. This might include 
interventions impacting on symptoms conceptual thinking such as rumination/worry postponement, 
detached mindfulness, and the challenging of metacognitions (Wells, 2008). It may also include 
techniques aimed at gaining greater attentional flexibility thus reducing symptoms focusing, such as 
the attentional training technique or situational attentional refocusing (Spada, Georgiou & Wells, 
2010; Wells, 2008). 
The items from the MaSCS use the word ‘symptoms’ rather than specifically referring to 
fatigue. This was by design as the authors hope that this new instrument could be validated in other 
conditions, for example where physical symptoms persist in the absence of a causative diagnosis, or 
after successful treatment of a condition when such persistent symptoms can no longer be attributed 
to the condition. 
This study is subject to several limitations that will have to be addressed by future research. 
First, social desirability, self-report biases, context effects, and poor recall may have contributed to 
errors in the self-report measurements. Second, the CFQ asks about a change in symptom severity 
over the previous month; it is plausible to assume that some patients may have been chronically ill 
for several years, entailing that a response to the item “no worse than usual” may still indicate 
severe experience of symptoms. This could affect the strength of the relationship between the newly 
developed instrument and levels of fatigue. Third, a cross-sectional design was adopted, and this 
does not allow causal inferences, and meant that the test-retest reliability of the new measure was 
not established. Fourthly, whilst anxiety and depression were controlled for, the presence of 
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personality disorder was not. Studies have suggested that the there is a high prevalence of 
personality disorder in CFS (Henderson & Tannock, 2004) and future studies that assess the clinical 
sensitivity of this newly developed self-report instrument will need to control for these constructs. 
Fifthly, this study utilizes self-report instrument to assess subjective experience and meta-awareness 
and as such, like much cognitive research, there is always doubt whether we are measuring the 
constructs we are intending to. Finally, the sample was moderate in size and many patients had 
received therapy. The 43 patients who had experienced CBT may have been exposed to the 
identification and exploration of cognitive constructs. However, standard CBT for CFS does not 
typically include the examination of metacognitions assessed here. This may be a stronger 
assumption because of the service from which participants were recruited. The service was one of 
the centres involved in the PACE trial (White et al., 2011) and many of its therapists were trained in 
the provision of protocol-driven manualized therapy whose sessions were often reviewed for 
treatment fidelity. Thus, the experience of treatment may not be particularly significant in 
explaining the current findings.  
However, despite these limitations, we believe that the MaSCS is a useful preliminary 
instrument for future research that aims to more robustly establish the role of metacognitions in 
CFS as well as other conditions presenting with both explained and unexplained symptoms. The 
MaSCS may also help to deepen our understanding of the mediating role of symptom focus and 
conceptual thinking about symptoms in the experience of symptoms.    
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Table 1: Factor Loadings for the Revised Instrument 
 
 Factor 1 Factor 2 
When I experience symptoms, it’s impossible to focus on anything else .129 622 
If I focus on the symptom I can take the appropriate action to get better .652 -.297 
Ruminating about my symptoms helps me to figure out how to deal with them .800 -.047 
Thinking about my symptoms makes me feel frustrated .032 .737 
If I don’t pay attention to my symptoms, I could push myself too far .600 .227 
Monitoring my symptoms helps me to predict how they will develop .793 .022 
Thinking about my symptoms makes me feel negative and down -.092 .885 
I monitor my symptoms so I can figure out my physical limitations .782 -.044 
Thinking about my symptoms makes me feel exhausted -.038 .745 
Monitoring my symptoms enables me to better control them .824 -.019 
Focusing on my symptoms makes me feel anxious or stressed -.125 .802 
Monitoring my symptoms helps to keep me safe .648 .129 
I am not able to stop thinking about my symptoms once I start .107 .681 
By focusing on my symptoms I can detect when I am getting better .753 -.054 
Not paying attention to my symptoms could lead to my illness getting worse .652 .229 
Focusing on my symptoms makes me feel down -.042 .831 
Thinking about my symptoms could make them worse .113 .524 
 
Table 2: Corrected Item-Total Correlations and Cronbach’s Alphas if Item Deleted 
 
 Corrected 
Item-Total 
Correlations 
Cronbach’s 
Alphas if 
Item 
Deleted 
Positive Metacognitions about Symptoms Control (Factor 1)   
If I focus on the symptom I can take the appropriate action to get better .486 .889 
Ruminating about my symptoms helps me to figure out how to deal with them .710 .872 
If I don’t pay attention to my symptoms, I could push myself too far .568 .883 
Monitoring my symptoms helps me to predict how they will develop .720 .870 
I monitor my symptoms so I can figure out my physical limitations .687 .873 
Monitoring my symptoms enables me to better control them .742 .868 
Monitoring my symptoms helps to keep me safe .592 .881 
By focusing on my symptoms I can detect when I am getting better .651 .876 
Not paying attention to my symptoms could lead to my illness getting worse .632 .878 
Negative Metacognitions about Symptoms Control (Factor 2)   
When I experience symptoms, it’s impossible to focus on anything else .557 .872 
Thinking about my symptoms makes me feel frustrated .634 .865 
Thinking about my symptoms makes me feel negative and down .799 .847 
Thinking about my symptoms makes me feel exhausted .642 .864 
Focusing on my symptoms makes me feel anxious or stressed .675 .861 
I am not able to stop thinking about my symptoms once I start .632 .865 
Focusing on my symptoms makes me feel down .734 .854 
Thinking about my symptoms could make them worse .471 .881 
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Table 3: Spearman’s Rho Correlation Matrix 
 
 Mean SD Range RAND SF-
36 PF 
DASS-21 
Depression 
DASS-21 
Anxiety 
MaSCS 
PMSC 
MaSCS 
NMSC 
CFQ 41.5 10.1 14-56 -.51** .52** .45** .24** 
 
.48** 
RAND SF-
36 PF 
51.2 24.7 0-100  -.41** 
 
-.38** 
 
-.09 
 
-.39** 
 
DASS-21 
Depression 
7.9 6.5 0-21   .71** 
 
-.0 .56* 
DASS-21 
Anxiety 
5.7 5.2 0-21    .13 
 
.48** 
 
MaSCS 
PMSC 
23.3 6.5 9-36     .12 
 
MaSCS 
NMSC 
18.4 5.9 8-32      
N=120, *p<0.05; **p<0.01. 
PMSC=Positive Metacognitions about Symptoms Control factor of the MaSCS. 
NMSC=Negative Metacognitions about Symptoms Control factor of the MaSCS. 
 
Table 4: Hierarchical Regression Model with CFQ as the outcome variable and DASS-21 and MaSCS as 
Predictor Variables. 
N=120, *p<0.05; **p<0.01. 
PMSC=Positive Metacognitions about Symptoms Control factor of the MaSCS. 
NMSC=Negative Metacognitions about Symptoms Control factor of the MaSCS. 
 
 β T P 
Step 1    
1. DASS-21 Anxiety 0.35 1.54 0.13 
2. DASS-21 Depression 0.53 2.90 0.04 
r2=0.24    
F Change=18.9    
Step 2    
1. DASS-21 Anxiety 0.19 0.83 0.41 
2. DASS-21 Depression 0.45 2.38 0.02 
3. MASCS PMSC 0.25 1.99 0.05 
4. MASCS NMSC 0.33 2.07 0.04 
r2=0.55    
F Change=4.8    
